FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2025
0mins
Source: Globenewswire
FDA Fast Track Designation: OKYO Pharma's urcosimod has received Fast Track designation from the FDA for treating neuropathic corneal pain, a condition with no approved therapies, aimed at expediting its development and review process.
Innovative Treatment Approach: Urcosimod is designed to address severe eye pain through a novel mechanism targeting inflammation and nerve damage, with ongoing clinical trials to evaluate its efficacy in patients suffering from this debilitating condition.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
